Introduction
Systemic sclerosis (SSc) is characterized by a progressive fibrosis of the perivascular and interstitial connective tissues which can involve the skin, heart, lungs, kidneys, and the gastrointestinal tract. SSc is an uncommon, debilitating condition, associated to a vital risk linked to visceral extensions and has a high case-fatality rate among connectivitis. SSc begins in the vast majority of cases with a Raynaud's phenomenon, may have a limited or diffuse skin extension, and is often associated to arterial occlusions, digital ulcerations or necrosis. SSc clinical manifestations are heterogeneous and classifications distinguish limited to diffuse disease, depending on the distribution of the skin lesions and organ involvement [1] [2] [3] . There is today no curative treatment. Disease susceptibility differs according to sex, age and race, there is a notable familial clustering, and SSc incidence may be rising [4, 5] . The clinical management of the patients still remains a difficult challenge and the pharmacopeia offers limited choices to the clinician to bring relief to patients. Pulmonary, renal and myocardial complications have benefited from the introduction of angiotensin converting enzyme inhibitors, calcium pump inhibitors, prostacyclin analogs and endothelin antagonists. Based on recent pathophysiological insights, a number of novel agents are being developed [6] [7] [8] . 78 ]. Platelets also link coagulation to angiogenesis, through the proteolytic release of several cryptic angiogenic regulators [79] . VEGF is a critical angiogenic mediator in SSc (below) and its connections with platelets have been extensively studied. VEGF is transported by platelets [80] . Following binding to its receptor, VEGF induces EC survival, growth, permeability and migration. Other key angiogenic regulators secreted by platelets are platelet-derived growth factor (PDGF), transforming growth factor, (TGF)- and angiopoietins. The angiogenic response is dependent on a complex regulated balance between the generation of pro-and anti-angiogenic molecules, with reference to magnitude and temporal production sequence [81] . The angiogenic activity of VEGF can only be appreciated by integrating the action of other mediators present in the EC environment [82, 83] . PDGF, TGF- and angiopoietins are such mediators, acting in concert with VEGF for the stabilization of the vascular wall; their imbalanced expression has indeed been implicated in aberrant angiogenesis [82, 84] . Interestingly, there is a regulated differential secretion of proand anti-angiogenic mediators by platelets with reference to the nature of the agonist [85] .
Platelet-derived mediators participate to vascular tone regulation
The blood flow is dependent on the constriction/dilation of resistance arteries. Endothelium and periarterial autonomic nervous plexus provide essential controls of the vascular tone [86, 87] . ECs are a source of vasoactive mediators that regulate blood flow, including the relaxing factors nitric oxid (NO), prostacyclin (PGI2) or endothelium-derived hyperpolarizing factor and vasoconstrictive factors including thromboxane A2 or endothelin-1 [88, 89] . Recent progress has highlighted the involvement of platelets and platelet-derived MPs in the control of the vascular tone. The integrity of the endothelium appears central to the vasomotor response to platelets; on intact endothelium, platelet derived mediators, including serotonin and ADP, cause the release of relaxing factors by the endothelium. If endothelium dysfunction has occurred, the absence of its protective role allows platelet-derived mediators, including serotonin and thromboxan A2 to induce vasoconstriction by directly acting on smooth muscle cells [90, 91] . Interestingly, VEGF may prove to have an increasing importance in vascular flow regulation, apart from its role in angiogenesis. Recent evidences indicate that it preserves the structure and function of neuro-effectors junctions [87] .
Platelets are a source of fibrogenic mediators
Platelets are a rich source of pro-fibrotic molecules. Tissue fibrosis results from a deregulated wound-healing response to chronic injury. It is typically associated to a perpetuating inflammatory response, resulting for example from the persistence or repeated release of a tissue irritant, in contrast to the regulated acute inflammatory response that ends in a resolution step, repair of tissue damage and tissue homeostasis [92] . A central feature of tissue fibrosis is a quantitatively and qualitatively altered production of ECM. The increased biosynthesis of ECM components, particularly fibrillar collagens, by fibrocompetent cells contributes to generate a permanent and destructive tissue scarring that impairs organ function. Fibrocompetent cell activation is therefore at the root of the natural history of tissue fibrosis, and one of its decisive manifestations is transdifferentiation towards myofibroblasts, expressing -smooth muscle actin (SMA), and harboring characteristic stress fibers and contractile phenotype [93] . It is generally accepted that the major source of myofibroblasts are local connective tissue fibroblasts. However, they can also be recruited from circulating fibrocytes and bone marrow-derived mesenchymal precursors, or they can derive from local epithelial and endothelial cells through the epithelial-mesenchymal transition [94] [95] [96] [97] [98] [99] . Multiple soluble signals activate fibrocompetent cells. Among the most studied in SSc are the growth factors TGF-1, PDGF, endothelin-1 and connective tissue growth factor. These mediators are potent fibroblast activators. TGF-1 holds a peculiar position in SSc, as its deregulated expression represents a critical step. TGF-1 promotes myofibroblastic transdifferentiation of quiescent fibroblasts, clearly demonstrated by the induction of -SMA [100] , stimulates their proliferation and the synthesis of ECM components, including fibrillar collagens. Epithelial-mesenchymal transition is linked to inflammation and fibrosis and several pro-fibrotic mediators induce the epithelialmesenchymal transition [101] . A hierarchical induction of pro-fibrotic mediators in tissue fibrosis has been emphasized [102] . Chemokines, as monocyte chemotactic protein MCP-1, RANTES (regulated upon activation, normal T-cell expressed and secreted), interleukin (IL)-8, activate fibrogenic cells, including skin fibroblasts, stimulating their proliferation, chemotaxis, and ECM biosynthesis. The interaction between keratinocytes and fibroblasts is a critical step during the early phase of wound healing in the skin. Fibroblasts produce keratinocyte growth factor and, conversely, keratinocytes signal to fibroblasts leading to their activation, production of a variety of cytokines/chemokines/angiogenic mediators, induction of ECM component synthesis and -SMA expression [102, 103] . There are important connections between vascular remodeling, angiogenesis and tissue fibrosis. Deregulated vascular remodeling is an important parameter in promoting the development of fibrosis and an imbalance between the production of angiogenic and antiangiogenic factors, such as CXC chemokines, at sites of tissue injury, is relevant to tissue fibrosis [17, [104] [105] [106] . Finally, a regulated balance between ECM production and degradation is a sine qua non condition for harmonious wound repair and tissue regeneration. Indeed, as shown in humans and in experimental tissue fibrosis models, the increased expression of some of TIMPs, a family of enzymes that control MMP activity through the inhibition of their proteolytic activity and the control of proform cleavage, leads to an altered MMP/TIMP balance, ECM homeostatic degradation/production disequilibrium, and ECM accumulation [107] . Platelets are essential actors in these mechanisms. They transport and secrete most of above -mentioned pro-fibrotic mediators, angiogenic and anti-angiogenic mediators, including CXC chemokines, ECM components and ECM remodeling proteins MMPs and TIMPs [108, 109] . Platelets influence cell growth and differentiation in a variety of situations [110] . They provide key control signals to angiogenesis. Persistent platelet activation in the microvascular bed may therefore contribute to tissue fibrosis [111] [112] [113] . However, few studies have considered their potential contribution. In fact, platelet-derived mediators have only recently being acknowledged as being of key importance in fibrosis as observed in liver and pulmonary diseases and, very recently, in SSc (below).
Evidence for platelet activation in SSc
There are signs of platelet activation in SSc, as indicated by measurements of various soluble and membrane-bound markers, circulating MPs and platelet-and plateletleukocyte aggregates (Table 1 ). Soluble markers have been largely studied. As there are signs of ongoing EC injury in SSc, the specificity of these markers is an important point. P-selectin (CD62p) is a component of -granules and of intracellular EC storage organelles. There has been debate whether the increase in plasma CD62p truly reflects platelet activation, as it is also expressed on activated ECs. It is however currently clear that most, if not all, measured plasma CD62p has a platelet origin [114, 115] . Activated ECs have also been discussed as potential contributors to soluble CD154 (sCD154). In fact, correlation studies demonstrated that it can be considered as mostly derived from platelets [116] , but, recently, other cell sources have been described, that may potentially contribute to elevated circulating sCD154 levels [117] . Soluble P-selectin glycoprotein ligand-1 is elevated in SSc [118] , which may also reflect some degree of platelet activation as it is expressed by platelets [119] . Chemokine (C-X-C motif) ligand-4 (CXCL4, Platelet Factor 4) is elevated in SSc; albeit until recently described as exclusively derived from platelets, other sources exist such as T-cells or macrophages that may be contributors to elevated circulating levels [120] . Tissue-plasminogen activator (tPA) has also been described as a marker of EC damage [121] . Studies of the expression of platelet membrane-bound activation markers also show that platelets are not globally activated, but that this activation concerns a fraction of their population [122] . Correlation studies in general do not evidence relations with clinical features of the disease, but this is a matter of debate as correlations were found for some markers such as sCD154, thromboxane B2 or MPs (Table  1) . Finally, morphological electron microscopy-based studies also suggest platelet enhanced activability in SSc, and there are signs of platelet granule release [111, 123, 124] . A major point is that platelet activation may be prominently linked to the Raynaud's phenomenon. Indeed, features of platelet activation are also found in the primary Raynaud's phenomenon (below).
Platelet activation markers Correlations with disease features References
Circulating platelet aggregates Not found [125] [126] [127] Platelet-leucocyte aggregates Not found [128] [128] -TG Not found [122] ; [130] [122]; [125] [126] [127] ; [129] [130] [131] [132] [133] [134] ;
Serotonin Not found [135] (in the CREST variant); [136] (also in platelets)
CXCL4
Not found [126] ; [131] 2]). Other abbreviations are spelled in the text.
Lack of platelet morphological abnormalities and count in SSc
There are no specific recognized abnormalities of the platelet count in SSc. Moderate thrombocytosis or thrombocytopenia are occasionally observed, and have been related to inflammation or microangiopathy, respectively [145, 146] . Platelet morphology is not altered.
Potential mechanisms mediating platelet activation in SSc
Mechanisms underlying platelet activation in SSc remain ill-defined. Questions that have been pursued are: (i) is there a platelet dysfunction in patients that would reduce the threshold level of platelet response to activating signals? (ii) are platelets activated in SSc as the result of EC injury, autoantibodies directed at platelets or other reasons? (iii) what is the role played by the Raynaud's phenomenon?
Is there a platelet disorder in SSc leading to platelet hyperactivability?
Several studies have examined the eventuality of platelet dysfunction in SSc ( Table 2) . Reports suggest augmented responsiveness of platelets to their physiological agonists, either strong agonists, such as thrombin or collagen, or weak agonists, such as serotonin, ADP, epinephrine or arachidonic acid, resulting in a reduced threshold of platelet aggregation to the agonist stimulus. Conversely, there is a reduced response to inhibitors of platelet activation such as prostacyclin. However, there are contradictory reports ( Table 2) . Platelet r e s p o n s e t o a g o n i s t s a s m e a s u r e d b y t h e hyperactive phenotype is often difficult to interpret. There is a significant variability between individuals, as several genetic modifiers may influence platelet function and as platelet hyperactivity, as measured by aggregometry, can be detected in healthy individuals [147, 148] . Also, in vivo, platelet activation results from the combinational input of agonists that act in a complex synergistic way and vary from donor to donor [149] [150] [151] [152] . The application of neural networks approaches for predicting platelet response to a complex milieu may represent a useful tool for studying platelet activation response to agonists in SSc. There are no straightforward interpretations of changes in platelet function in SSc. Interestingly, binding assays of radiolabelled collagen indicate a specific increase in the expression of the platelet collagen type 1 receptor in SSc patients [153] , which would explain the enhanced response to collagen and indicate a 37 primary or acquired defect. Proteomic studies on platelet compartments in SSc patients could help finding a potential primary or acquired platelet defects in this disease.
Platelet function changes References
Hyperaggregability Spontaneous (in whole blood) In response to agonists [126] ; [131] ; [154] [155] [156] [157] [158] Enhanced adhesion to collagen [159] ;
Reduced sensitivity to PGI2 [160] Increased platelet sensitivity to collageninduced aggregation [138] ; [157] Increased expression of collagen type 1 receptor [153] Hyperaggregability not found [161] 
Potential mechanisms mediating platelet activation in SSc
Platelet activation in SSc may first be the consequence of endothelium injury. Indeed, the canonical role of platelets is to react to endothelium damage, a circumstance that activates a bidirectional dialogue between ECs and platelets, initiating and sustaining inflammation. Through soluble and platelet-bound signals, activated platelets confer ECs a proinflammatory and procoagulant phenotype and, reciprocally, EC activation, as met in inflammation, leads to platelet activation resulting in a pro-inflammatory amplification loop. The balance of signals that keep platelet from being activated may be overcome in a variety of conditions. As summarized above, not only platelets react to the endothelial barrier loss of integrity with consequent exposure of the underneath collagen-rich matrix, but they also react to slighter features of EC activation, which do not lead per se to severe endothelium damage, as met for example in conditions in which ECs are activated by cytokines including TNF IL-1, VEGF, by oxidative stress or hypoxia [80, [162] [163] [164] [165] . These signals induce the expression of a range of molecules promoting platelet adhesion on ECs. Platelets bind to these docking structures, an event that initiates their activation. These conditions also induce ECs to produce platelet agonists, such as multimeric vWF and ADP. Inflammation and coagulation are inextricably linked. Activated ECs express tissue factor, leading to the activation of coagulation, platelet activation, thrombin generation and further amplification of the inflammatory reaction. This is dramatically exemplified in renal involvement in SSc, characterized by thrombotic microangiopathy lesions. On electron microscopy studies, aggregates of platelets admixed with fibrin and fragmented red blood cells are observed within small interstitial vessels or glomerular capillaries. Hypoxia is a noxious stimulus that activates a range of inflammatory pathways, leading to EC activation through multiple mechanisms, including the production of angiogenic factors [166] [167] [168] .
Hypoxia is thought to play a critical role in SSc. SSc-associated microangiopathy results in a disturbed blood flow in the capillaries with consequent hypoxia, which is likely to be aggravated by tissue fibrosis [169] [170] [171] [172] . Hypoxia alters vascular endothelium but also directly activates platelets [173, 174] (our unpublished results). Altogether, conditions that turn EC phenotype to proinfammatory/prothrombotic are translated into platelet adhesion and activation, with the consequent release of inflammatory, mitogenic, angiogenic and fibrogenic platelet-derived mediators described above. These mediators further activate ECs, promoting the production of cytokine/chemokines, induction of adhesion and procoagulant molecules, and production and activation of MMPs. Moreover, ECs undergoing apoptosis become proadhesive for platelets [175] , and activated platelets can in turn induce EC apoptosis [176] .
In fact, endothelial injury in the microcirculation and arterioles is a predominant feature of SSc which has extensively been reviewed [13, 30, [177] [178] [179] [180] . There are circulating stigmata of endothelial injury, including von Willebrand factor and supranormal (larger) vWF multimers [126, 131, 139, [181] [182] [183] [184] , soluble adhesion molecules, such as E-selectin or vascular cell adhesion molecule (VCAM)-1 and ICAM-1, thrombomodulin, tPA, or endothelin [185] [186] [187] [188] . Increased nitrate in the plasma or serum of patients has been described, and been related to EC injury, as there are correlations with soluble E-selectin and soluble VCAM-1 [189, 190] . Elevated circulating ECs were also attributed to vascular damage in SSc [191] . EC apoptosis is a common and early feature in SSc [192] ; however pathologic evidence for EC apoptosis remains controversial [177] . However there are inherent limitations to the interpretations of such biomarkers [193] , these results show that there is an early insult to the vasculature during the course of the disease. Importantly, the Raynaud's phenomenon itself, one, if not the first manifestation of SSc, preceding the onset of other symptoms of the disease [194] [195] [196] [197] [198] , is associated with platelet activation [132] . The absence of endothelium abnormalities in the primary Raynaud's phenomenon is generally accepted, although limited morphological abnormalities have been described [199] . However, features of platelet activation are found in primary Raynaud's phenomenon [158, 200, 201] and platelet activation was proposed to play a role in its pathogenesis [135, 202] . Therefore, events responsible for the Raynaud's phenomenon lead to platelet activation in the absence of EC damage, a possible argument to place platelet activation as a very early pathogenic event in the reciprocal activation dialogue between platelets and ECs. Intriguingly, several factors that have been put forward as being potentially causative or susceptible to modify the progression of SSc, as exposure of extremities to cold, mechanical vibrations, exposure to organic solvents or silica, CMV infection are associated to some extent to platelet activation, and for some of them to trigger the Raynaud's phenomenon. Finally, autoantibodies against platelet gpIIb/IIIa have been described in SSc [203] . However their role in platelet activation remains uncertain.
Platelet activation and the progression of SSc
SSc is a complex disease for which no specific causative mechanism has been identified. The disease may be initiated in the vasculature, as morphological changes are apparent before the onset of the disease; however, it is not clear how endothelium injury begins. Platelets play a large and complex physiological role in health and disease, as they contribute to hemostasis, inflammation, tissue repair, and to the innate and adaptative immunity, standing as essential links [69, 204] . Platelets establish intimate bidirectional relationship with the endothelium, making them potential contributors to SSc vasculopathy. The microcirculation is a characteristic target in SSc pathogenesis. Microcirculation hemorheologic conditions result in an intimate platelet/endothelium interface, characterized by a near capillary wall platelet concentration. Clearly, cross-interactions between ECs and platelets are inextricably linked under the form of feed-back activation loops and whether or not being a primary event, any condition leading to an endothelium insult drives platelet activation. Conversely, platelet activation drives to EC activation; the fact that platelet activation is observed in the primary Raynaud's phenomenon, in the absence of EC detectable damage, may signify that subtle early events activating platelets, such as disturbed blood flow or hypoxia, precede the onset of the disease. Following platelet activation in the microcirculation, as described above, a wide array of soluble and plateletbound mediators with a pleiotropic range of actions are released that can contribute to several pathophysiological features of the disease including (i) vascular tone dysregulation, (ii) endothelium activation, (iii) inflammation, (iv) activation of the coagulation system, (v) fibrogenic response, (vi) altered angiogenesis. Apart from the possible deleterious cross-talk between endothelium and platelets, described above, two chief features of SSc progression that may be connected to platelets have been the subject of very recent reports. Altered angiogenesis and progressive perivascular and interstitial fibrosis are hallmarks of SSc [27] . First as summarized above, platelets are essential contributors to angiogenesis during wound healing, and ongoing platelet activation in capillary beds may be involved in the altered angiogenesis associated with SSc. In fact, in line with the major VEGF transporter role of platelets, platelet VEGF is increased in SSc patients. However, this is not the case for other angiogenic regulators, such as TGF-1, PDGF-BB or angiopoietins [122] . VEGF, jointly with other mediators, determines the angiogenic or non-angiogenic status of the EC and an imbalance between the relative concentrations of angiogenic mediators is likely to alter angiogenesis homeostasis [170, 177] . Indeed, the deregulated expression of VEGF is thought to lead to abnormal angiogenesis, as exemplified by the resulting disorganization of the capillary network with large, leaky, fragile capillaries; dynamic parameters, such as the magnitude or the kinetics of VEGF release being critically important [170, [205] [206] [207] . Therefore platelet activation in the patient's microvascular beds may result in the release of inappropriate combinations of angiogenic and angiostatic mediators, and such disequilibrium may be relevant to the vascular disease in SSc [122, 208, 209] . Further, as summarized above, there are connections between angiogenesis, vascular remodeling and fibrosis and an unbalance between factors promoting and factors inhibiting angiogenesis may also be relevant to the progression of fibrosis. Second, as summarized above, platelets provide a cornucopia of mediators that may be relevant to the natural history of tissue fibrosis, i.e. through fibrocompetent cell activation. Sustained activation of fibrocompetent cells contribute to excessive ECM production in tissues. Indeed, fibroblasts expanded from the fibrotic skin or lungs from SSc patients have a myofibroblastic phenotype and there is a strong correlation between myofibroblast labeling in the lesional skin and the Rodnan skin score [210] . Crucial platelet links with tissue fibrosis have recently been emphasized in humans. In liver fibrosis the secretion of platelet-derived CXCL4 is instrumental [211] . In SSc, the role of platelet-derived serotonin in skin fibrosis is strongly suggested by the stimulation of the production of ECM by serotonin through binding to dermal fibroblasts serotonin receptor 5-HT 2B , increased expression of 5-HT 2B in the fibrotic skin of SSc patients and reduction of experimental fibrosis through pharmacological targeting of the 5-HT/5-HT 2B signaling and anti-platelet drugs [212] .
Conclusion; Platelet activation in SSc: A deleterious loop?
The primary triggering event in SSc remains unclear. However, inflammation of the vasculature is a common denominator, whether resulting from an autoimmune response to a yet undefined antigen or other mechanisms. Whatever the primary target, inflammation leads to EC activation and, due to the reciprocal activating interplay between platelets and endothelium, EC activation in turn activates platelets and vice-versa. Platelet activation, through the release of cytokines, chemokines, angiogenic and chemotactic mediators...., amplifies the inflammatory reaction by triggering its many facets, including leukocyte recruitment, leading to further endothelium activation and perivascular inflammation, deregulated angiogenesis and, eventually, fibrosis (Figure 1) . A chronic inflammatory scenario may contribute to fibrosis by the way of fibrocompetent cell activation, if the initial pathogenic trigger persists, either continuously or repetitively. Self-sustained myofibroblastdependent fibrotic process takes place on the grounds of a chronic inflammation. Platelets may therefore stand at an important place in the ill-understood hierarchy of cell and soluble mediators interplay responsible for the disease. This scenario is evidently highly simplified due to the extreme complexity and heterogeneity of the disease pathophysiology. The lack of suitable animal models [213, 214] that would accurately recapitulate each steps of SSc progression remains a real handicap to understand the natural history of this disease. This schematic model underlines the potential role that platelets may play in the initiation and progression of SSc; see text for details. The role of platelet-derived MPs may also be an important point to consider, as they recapitulate several platelet functions and may transfer platelet deleterious effects at sites distant from their generation.
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